Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Operating Expenses (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Operating Expenses for 9 consecutive years, with $49.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 37.93% to $49.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $260.9 million through Dec 2025, down 13.19% year-over-year, with the annual reading at $260.9 million for FY2025, 13.19% down from the prior year.
  • Operating Expenses hit $49.7 million in Q4 2025 for Sutro Biopharma, down from $58.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $85.9 million in Q1 2025 to a low of $33.7 million in Q1 2021.
  • Historically, Operating Expenses has averaged $58.1 million across 5 years, with a median of $57.2 million in 2022.
  • Biggest five-year swings in Operating Expenses: surged 51.87% in 2021 and later crashed 37.93% in 2025.
  • Year by year, Operating Expenses stood at $45.7 million in 2021, then rose by 26.62% to $57.9 million in 2022, then increased by 21.98% to $70.6 million in 2023, then grew by 13.46% to $80.1 million in 2024, then crashed by 37.93% to $49.7 million in 2025.
  • Business Quant data shows Operating Expenses for STRO at $49.7 million in Q4 2025, $58.2 million in Q3 2025, and $67.1 million in Q2 2025.